http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009239929-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_834770c5a312dd667bc193639a293b08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9458d03d014597c61ac16a6c39ddbb35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12b83a730b52b2382550df9ef17a34bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2605b64cfb301dcec258810c2e90de8f |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-14 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-14 |
filingDate | 2005-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4c63474efcbdc9a9e7d4001b7586592 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09c327453d3c19db4fbbc1fd637705ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d278c0fa34883dc9955157f5dde25df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42082e0586772c34d6e344f140ab9518 |
publicationDate | 2009-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2009239929-A1 |
titleOfInvention | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors |
abstract | A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R 1 is H, C 1-6 alkyl, —C(A)D, C 3-8 cycloalkyl, aryl, het, aryl-C 1-4 alkyl or het-C 1-4 alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted; A is S or O; D is H, C 1-6 alkyl, aryl, het, aryl-C 1-4 alkyl or het-C 1-4 alkyl; aryl represents phenyl, naphthyl, anthracyl or phenanthryl; het represents an aromatic or non-aromatic 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6-membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom; R 2 is aryl 1 or het 1 , each optionally substituted; n is 1 or 2, provided that when n is 1, m is 0 or 1 and when n is 2, m is 0, wherein if m is 0, then * represents a chiral centre; R 3 is (CH 2 ) a E, wherein a is 0, 1 or 2 and E is a group selected from: Formula (i) wherein: X is O, S, NR 12 , (CH 2 ) v or a bond; b is 1, 2, 3 or 4; c is 1, 2 or 3; v is 1 or 2; R 10 and 11 are each independently H or C 1-4 alkyl; and R 12 is H, 1-6 alkyl, C(O)C 1-6 alkyl, SO 2 —C 1-6 alkyl; and wherein one or more pairs of hydrogen atoms on adjacent carbon or nitrogen atoms may be replaced by a corresponding number of double bonds, provided the ring system is not aromatic; Formula (ii) a carbocyclic spiro group containing 6 to 12 carbon atoms; Formula (iii) wherein: d is 1, 2, 3 or 4; a is 1, 2 or 3; f is 1 or 2; and R 30 is H or C 1-4 alkyl; and wherein one or more pairs of hydrogen atoms on adjacent carbon atoms may be replaced by a corresponding number of double bonds, provided the ring system is not aromatic; Formula (iv) wherein: g is 0, 1, 2 or 3; J is NR 40 ; and R 40 is C(O)C 1-6 alkyl, S0 2 -C 1-6 alkyl; Formula (v) wherein: h is 0, 1, 2 or 3; and R 50 is H, C 1-8 alkyl, C 1-8 alkoxy, OH, halo, CF 3 , OCF 3 , SCF 3 , hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl and C 1-4 alkyl-S—C 1-4 alkyl; Formula (vi) —CH(cyclopropane) 2 ; Formula (vii) C 1-6 alkyl, substituted by at least one substituent; and Formula (viii) C 3-8 cycloalkyl-C 1-6 alkyl; wherein the C 1-6 alkyl moiety is substituted at any point other than at the junction with the C 3-8 cycloalkyl moiety, by at least one substituent. The compounds exhibit activity as both serotonin and/or noradrenaline re-uptake inhibitors and therefore have utility in a variety of therapeutic areas, for example urinary incontinence. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015134503-A1 |
priorityDate | 2004-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1995.